Top Markets
Coin of the day
Hubei Biocause Pharmaceutical Co., Ltd. Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627
Rang in aandelen #9082
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a... Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
Aandeelprijs
$0.2219522
Laatst gesynchroniseerd: 2025-09-11
Marktkapitalisatie
$1.10B
Verandering (1 dag)
0.04%
Verandering (1 jaar)
0.17%
Land
CN
Handel Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Winst voor Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Winst in Sep 2024 TTM: $-246.31M
Volgens de meest recente financiële verslagen van Hubei Biocause Pharmaceutical Co., Ltd. bedraagt de huidige winst van het bedrijf $-246.31M. In 2022 behaalde het bedrijf een winst van $32.59M, een daling ten opzichte van de winst van 2021, die $53.98M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Hubei Biocause Pharmaceutical Co., Ltd. van 2000 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-246.31M -6.66%
2023 $-263.90M -909.84%
2022 $32.59M -39.64%
2021 $53.98M -75.67%
2020 $221.88M -57.48%
2019 $521.80M 36.14%
2018 $383.27M -8.47%
2017 $418.73M -15.31%
2016 $494.40M 859.98%
2015 $51.50M 192.79%
2014 $17.59M -182.99%
2013 $-21.20M -981.31%
2012 $2.40M -112.99%
2011 $-18.51M -493.30%
2010 $4.71M -45.74%
2009 $8.67M 709.23%
2008 $1.07M -93.04%
2007 $15.40M 107.42%
2006 $7.42M 610.69%
2005 $1.04M 72.62%
2004 $605.05K -110.58%
2003 $-5.72M -392.76%
2002 $1.95M -72.00%
2001 $6.97M 18.03%
2000 $5.91M 0.00%
Winst van vergelijkbare bedrijven of concurrenten